Cinacalcet Therapy in Primary Hyperparathyroidism

Patient Characteristics

• The patient presents with Stage 3b CKD (eGFR 41 mL/min/1.73m²) and elevated PTH (97 pg/mL), suggesting primary hyperparathyroidism given the hypercalcemia 1

Safety Considerations

• Cinacalcet increases the risk of hypocalcemia 7-fold overall (RR 7.38) 2, 3
• Nausea (RR 2.05) and vomiting (RR 1.95) are common gastrointestinal side effects of cinacalcet 2, 3, 4

Mortality and Morbidity

• Cinacalcet prevents parathyroidectomy (RR 0.49) in patients where surgery is contraindicated 2, 3, 5